Chris Williams: New analysis of CD3/CD8 TILs in QUASAR trial

Chris Williams, Medical oncologist at Leeds Hospitals, shared on X:

“Adjuvant chemotherapy decisions are complex in stage 2 colon cancer.

New analysis of CD3/CD8 TILs in QUASAR trial.

1st in early CRC RCT (colorectal cancer randomized controlled trial)

Stronger prognostic effect than any routinely measured stage 2 ‘high risk’ feature

High vs low CD3 Score = 3x 5 years recurrence risk.”

Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial

Authors: Christopher J.M. Williams, Richard Gray, Robert K. Hills, Michael Shires, Liping Zhang, Zuo Zhao, Tracie Gardner, Nancy Sapanara, Xiao-Meng Xu, Isaac Bai, Dongyao Yan, Andrea Muranyi, Sarah Dance, Faranak Aghaei, Gemma Hemmings, Michael Hale, Uday Kurkure, Christoph Guetter, Susan D. Richman, Gordon Hutchins, Jenny F. Seligmann, Nicholas P. West, Shalini Singh, Kandavel Shanmugam and Philip Quirke.

Source: Chris Williams/X